Recent news on Leukeran

Expanded Label Filed for Campath®  -  Apr 9, 2007
Cancer Consultants (press release),The sBLA submission is based on results from a phase III clinical trial directly comparing Campath to chlorambucil (Leukeran®) as initial therapy for the

Idera Pharmaceuticals sells licenses to Merck  -  Dec 12, 2006
Boston Globe,The study compared the drug with GlaxoSmithKline PLC's Leukeran and found that Campath reduced the risk of disease progression or death by 42 percent,

Idera Pharmaceuticals sells licenses to Merck  -  12 Dec 2006
Boston Globe,The study compared the drug with GlaxoSmithKline PLC's Leukeran and found that Campath reduced the risk of disease progression or death by 42 percent,

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional